公司资料
Savara, Inc. 股价、新闻与催化剂
- 股票代码:
- SVRA
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
5.56 USD (-0.54%)
收盘价
最后更新: 2026年8月24日
1.08B USD
市值
股价为何变动
As of Aug 24, 2026, SVRA closed down 0.54% at $5.56. No new same-company headline was identified in the current news window.
公司概览
业务概览
Savara is a respiratory company focused on rare lung disease and inhaled therapies. Its story is built around severe pulmonary conditions with limited treatment options.
所在地与行业分类
Headquartered in the United States and listed on NASDAQ, Savara sits in specialty biopharma.
商业模式特征
The company depends on clinical data, inhaled-delivery execution, and the ability to build a rare-respiratory franchise.
生物医药行业定位
Savara is a niche respiratory biotech whose stock is tightly linked to trial and regulatory progress.
未来催化剂
- Savara’s next catalyst is MOLBREEVI in autoimmune pulmonary alveolar proteinosis, with regulatory and launch-readiness steps doing most of the work. The key question is whether the program can keep moving toward a real rare-disease commercial opportunity.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。